Industry
Biotechnology
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 9:41 am
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 9:05 pm
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 10:18 am
Portfolio Pulse from Benzinga Newsdesk
June 20, 2024 | 5:45 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 3:14 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 10:44 am
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 9:26 pm
Portfolio Pulse from Benzinga Newsdesk
April 10, 2024 | 11:19 am
Portfolio Pulse from Avi Kapoor
March 12, 2024 | 1:17 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.